Latest Orally disintegrating tablet Stories
Catalent’s Zydis® Technology Used to Develop Thermo Stable and Cold-Chain Independent Vaccines Somerset, NJ (PRWEB) April 20, 2015 Catalent, the
Catalent has completed prototype formulation development and is delivering drug supplies for Biohaven's lead clinical product. TORONTO, March 24, 2015 /PRNewswire/ - Portage
HAYWARD, Calif., Jan. 26, 2015 /PRNewswire/ -- Impax Laboratories, Inc. (NASDAQ: IPXL) announced today that the U.S.
- Company awarded 180 days of marketing exclusivity - PITTSBURGH, Dec. 11, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced the U.S.
Catalent Pharma Solutions, the global leader in drug development solutions and advanced delivery technologies for pharmaceutical, biologic and consumer health products, was recently invited by
MIAMI, April 22, 2014 /PRNewswire/ -- Fuisz Pharma llc today announced the filing of a patent application with the U.S.
Experts from Catalent Pharma Solution will present ‘Overcoming the Compliance Challenge: Formulation Technology to Improve Acceptance & Adherence’ at the forthcoming Crops & Chemicals
New site to feature proprietary orally disintegrating tablet (ODT) platform, Pharmaburst 500 WILMINGTON, Del., Jan.
Two poster presentations will be given by Abhijit Gokhale, Ph.D., Senior Scientist, Formulation and Process Development, Patheon Inc., on Monday, July 22 and Tuesday, July 23. (PRWEB)